Therapeutic effect of fluvastatin on medication‐related osteonecrosis of the jaw

Sanda, Koma; Ayukawa, Yasunori; Yasunami, Noriyuki; Adachi, Naomi; Furuhashi, Akihiro; Imai, Masanori; Matsunaka, Ken; Koyano, Kiyoshi

doi:10.1002/jper.21-0294

Cited by 10 publications

(3 citation statements)

References 36 publications

(78 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, short-term use of statins was shown to have many bene cial effects on oral health [44], including aiding the healing of the extraction socket [45]. In fact, uvastatin and atorvastatin have therapeutic effects on MRONJ and/or can act protectively [46,47,48,49]. This is in line with the decreased risk of osteonecrosis of the femoral head when glucocorticoids are combined with statins [50].…”

Section: Discussionmentioning

confidence: 99%

Single low-dose of denosumab as a triggering agent for MRONJ development in a patient with osteoporosis Case report and mini-review

Szaraz

Peřina

Treglerová

et al. 2023

Preprint

View full text Add to dashboard Cite

Both denosumab (DNO) and bisphosphonates (BP), antiresorptive drugs (ARDs) used for the treatment of osteoporosis and oncological disorders, are known for their potential to cause medication-related osteonecrosis of the jaws (MRONJ). Besides ARDs, statins were recently associated with MRONJ development, especially in patients taking higher doses of statins for a longer period of time. Here, we report a case of a woman with osteoporosis who rapidly developed MRONJ stage III after only a single low dose of DNO. The patient was taking statins (rosuvastatin) for 7 years and had also been on BP (alendronate) for 4 years previously but this treatment was discontinued for approximately 1.5 years before MRONJ development. We performed a literature review of cases with MRONJ triggered by a single low dose of DNO and of cases with statin-induced MRONJ in patients not using ARD. Because the MRONJ development after a single low dose of DNO is rare, only eleven cases were previously described. We suggest that (i) in some patients, long-term use of statins and BP may lead to a higher susceptibility of MRONJ development after DNO exposure and (ii) that all predisposing factors to MRONJ development including the necessity of any dental procedures should be considered before DNO therapy is initiated.

show abstract

Section: Discussionmentioning

confidence: 99%

Single low-dose of denosumab as a triggering agent for MRONJ development in a patient with osteoporosis Case report and mini-review

Szaraz

Peřina

Treglerová

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Statins are implicated in bone metabolism and statin therapy lowers risk of osteonecrosis in steroid therapy [ 67 ]. Preclinical data has shown single topical Fluvastatin therapy may aid in the healing of BRONJ lesions [ 68 ]. Lithium was found to activate B catenin and protect from steroid-mediated osteonecrosis [ 69 ], and lithium nanoparticles may be useful in BRONJ prevention and management [ 70 ].…”

Section: Discussionmentioning

confidence: 99%

Bioinformatic Data Mining for Candidate Drugs Affecting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) in Cancer Patients

Zhuang

Zhou

et al. 2022

Disease Markers

View full text Add to dashboard Cite

Background. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) leads to significant morbidity. Other coadministered drugs may modulate the risk for BRONJ. The present study aimed to leverage bioinformatic data mining to identify drugs that potentially modulate the risk of BRONJ in cancer. Methods. A GEO gene expression dataset of peripheral blood mononuclear cells related to BRONJ in multiple myeloma patients was downloaded, and differentially expressed genes (DEGs) in patients with BRONJ versus those without BRONJ were identified. A protein-protein interaction network of the DEGs was constructed using experimentally validated interactions in the STRING database. Overrepresented Gene Ontology (GO) molecular function terms and KEGG pathways in the network were analysed. Network topology was determined, and ‘hub genes’ with degree ≥2 in the network were identified. Known drug targets of the hub genes were mined from the ‘drug gene interaction database’ (DGIdb) and labelled as candidate drugs affecting the risk of BRONJ. Results. 751 annotated DEGs ( log FC ≥ 1.5 , p < 0.05 ) were obtained from the microarray gene expression dataset GSE7116. A PPI network with 633 nodes and 168 edges was constructed. Data mining for drugs interacting with 49 gene nodes was performed. 37 drug interactions were found for 9 of the hub genes including TBP, TAF1, PPP2CA, PRPF31, CASP8, UQCRB, ACTR2, CFLAR, and FAS. Interactions were found for several established and novel anticancer chemotherapeutic, kinase inhibitor, caspase inhibitor, antiangiogenic, and immunomodulatory agents. Aspirin, metformin, atrovastatin, thrombin, androgen and antiandrogen drugs, progesterone, Vitamin D, and Ginsengoside 20(S)-Protopanaxadiol were also documented. Conclusions. A bioinformatic data mining strategy identified several anticancer, immunomodulator, and other candidate drugs that may affect the risk of BRONJ in cancer patients.

show abstract

“…Miscellaneous topical agents: local application of lactoferrin to sites of bone exposure was reported to enhance repair and improve wound closure following surgical treatment of MRONJ in an open label study [24]. Fluvastatin administered by local injection and by topical application in sites of MRONJ in animal models showed increased rate of healing, reduced necrotic bone, and new bone formation, supporting the potential in future clinical trials [25].…”

Section: Topical or Systemic Agents For Mronj Managementmentioning

confidence: 97%

Medication-Related Osteonecrosis of the Jaw: Successful Medical Management of Complex Maxillary Alveolus with Sinus Involvement

Epstein¹,

Arany²,

Yost³

et al. 2023

Case Rep Oncol

View full text Add to dashboard Cite

Medication-related osteonecrosis of the jaw (MRONJ) in cancer patients presents a considerable challenge in management. Current management is primarily based on interventions in a limited number of cases assessing a single approach. Medical management typically is reported to include antimicrobial therapy with or without surgery. Advances in the understanding of pathogenesis have led to the investigation of additional medical interventions for early-stage necrosis. We present 3 patients with advanced-stage MRONJ of the maxilla using combined medical modalities including antimicrobial therapy, photobiomodulation therapy, pentoxifylline, vitamin E, and synthetic parathyroid hormone. All patients had a good outcome and avoided surgical intervention. We also report biological and functional imaging that may assist in more effective diagnosis and management of MRONJ. The 3 patients reported suggest that combined medical management should be considered in all cases of MRONJ (including stage III) prior to determining if surgical intervention is required. Functional imaging with a technetium bone scan or positron emission tomography scan correlated with diagnosis and confirmed resolution in patients. We present 3 challenging MRONJ patients that were effectively managed with a combined medical and nonsurgical therapy that demonstrated good clinical outcomes avoiding surgical interventions.

show abstract

Therapeutic effect of fluvastatin on medication‐related osteonecrosis of the jaw

Cited by 10 publications

References 36 publications

Single low-dose of denosumab as a triggering agent for MRONJ development in a patient with osteoporosis Case report and mini-review

Single low-dose of denosumab as a triggering agent for MRONJ development in a patient with osteoporosis Case report and mini-review

Bioinformatic Data Mining for Candidate Drugs Affecting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) in Cancer Patients

Medication-Related Osteonecrosis of the Jaw: Successful Medical Management of Complex Maxillary Alveolus with Sinus Involvement

Contact Info

Product

Resources

About